Cargando…

A surgical strategy for intrahepatic cholangiocarcinoma — the hilar first concept

PURPOSE: The present study assesses long-term overall survival (OS) and disease-free survival (DFS) after curative resection for intrahepatic cholangiocarcinoma (ICCA) depending on resection margin (RM) status and lymph node (LN) status. METHODS: Clinical data of all consecutively resected patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Nevermann, Nora, Bode, Julia, Vischer, Maxine, Feldbrügge, Lina, Knitter, Sebastian, Krenzien, Felix, Pelzer, Uwe, Fehrenbach, Uli, Auer, Timo Alexander, Lurje, Georg, Schmelzle, Moritz, Pratschke, Johann, Schöning, Wenzel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404569/
https://www.ncbi.nlm.nih.gov/pubmed/37544932
http://dx.doi.org/10.1007/s00423-023-03023-y
_version_ 1785085327750201344
author Nevermann, Nora
Bode, Julia
Vischer, Maxine
Feldbrügge, Lina
Knitter, Sebastian
Krenzien, Felix
Pelzer, Uwe
Fehrenbach, Uli
Auer, Timo Alexander
Lurje, Georg
Schmelzle, Moritz
Pratschke, Johann
Schöning, Wenzel
author_facet Nevermann, Nora
Bode, Julia
Vischer, Maxine
Feldbrügge, Lina
Knitter, Sebastian
Krenzien, Felix
Pelzer, Uwe
Fehrenbach, Uli
Auer, Timo Alexander
Lurje, Georg
Schmelzle, Moritz
Pratschke, Johann
Schöning, Wenzel
author_sort Nevermann, Nora
collection PubMed
description PURPOSE: The present study assesses long-term overall survival (OS) and disease-free survival (DFS) after curative resection for intrahepatic cholangiocarcinoma (ICCA) depending on resection margin (RM) status and lymph node (LN) status. METHODS: Clinical data of all consecutively resected patients with ICCA at a single high-volume center between 2005 and 2018 were collected. Minimum follow-up was 36 months. Perioperative and long-term oncological outcome was assessed. RESULTS: One hundred ninety-two cases were included in the analysis. Thirty- and 90-day-mortality was 5.2% (n = 10) and 10.9% (n = 21). OS was 26 months with 1-, 2-, and 5-year-OS rates of 72%, 53%, and 26%. One-, 2-, and 5-year-DFS rates were 54%, 42%, and 35% (N0 vs. N1: 29 vs. 9 months, p = 0.116). R1 was not found to be an independent risk factor for reduced survival in the overall cohort (p = 0.098). When differentiating according to the LN status, clear resection margins were significantly associated with increased DFS for N0 cases (50 months vs. 9 months, p = 0.004). For N1 cases, no significant difference in DFS was calculated for R0 compared to R1 cases (9 months vs. 9 months, p = 0.88). For N0 cases, clear resection margins > 10 mm were associated with prolonged OS (p = 0.048). CONCLUSION: For N1 cases, there was no significant survival benefit when comparing R0 versus R1, while the complication rate remained high for the extended resection types. In view of merging multimodal treatment, the hilar first concept assesses locoregional LN status for optimal surgical therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00423-023-03023-y.
format Online
Article
Text
id pubmed-10404569
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-104045692023-08-08 A surgical strategy for intrahepatic cholangiocarcinoma — the hilar first concept Nevermann, Nora Bode, Julia Vischer, Maxine Feldbrügge, Lina Knitter, Sebastian Krenzien, Felix Pelzer, Uwe Fehrenbach, Uli Auer, Timo Alexander Lurje, Georg Schmelzle, Moritz Pratschke, Johann Schöning, Wenzel Langenbecks Arch Surg Research PURPOSE: The present study assesses long-term overall survival (OS) and disease-free survival (DFS) after curative resection for intrahepatic cholangiocarcinoma (ICCA) depending on resection margin (RM) status and lymph node (LN) status. METHODS: Clinical data of all consecutively resected patients with ICCA at a single high-volume center between 2005 and 2018 were collected. Minimum follow-up was 36 months. Perioperative and long-term oncological outcome was assessed. RESULTS: One hundred ninety-two cases were included in the analysis. Thirty- and 90-day-mortality was 5.2% (n = 10) and 10.9% (n = 21). OS was 26 months with 1-, 2-, and 5-year-OS rates of 72%, 53%, and 26%. One-, 2-, and 5-year-DFS rates were 54%, 42%, and 35% (N0 vs. N1: 29 vs. 9 months, p = 0.116). R1 was not found to be an independent risk factor for reduced survival in the overall cohort (p = 0.098). When differentiating according to the LN status, clear resection margins were significantly associated with increased DFS for N0 cases (50 months vs. 9 months, p = 0.004). For N1 cases, no significant difference in DFS was calculated for R0 compared to R1 cases (9 months vs. 9 months, p = 0.88). For N0 cases, clear resection margins > 10 mm were associated with prolonged OS (p = 0.048). CONCLUSION: For N1 cases, there was no significant survival benefit when comparing R0 versus R1, while the complication rate remained high for the extended resection types. In view of merging multimodal treatment, the hilar first concept assesses locoregional LN status for optimal surgical therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00423-023-03023-y. Springer Berlin Heidelberg 2023-08-07 2023 /pmc/articles/PMC10404569/ /pubmed/37544932 http://dx.doi.org/10.1007/s00423-023-03023-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Nevermann, Nora
Bode, Julia
Vischer, Maxine
Feldbrügge, Lina
Knitter, Sebastian
Krenzien, Felix
Pelzer, Uwe
Fehrenbach, Uli
Auer, Timo Alexander
Lurje, Georg
Schmelzle, Moritz
Pratschke, Johann
Schöning, Wenzel
A surgical strategy for intrahepatic cholangiocarcinoma — the hilar first concept
title A surgical strategy for intrahepatic cholangiocarcinoma — the hilar first concept
title_full A surgical strategy for intrahepatic cholangiocarcinoma — the hilar first concept
title_fullStr A surgical strategy for intrahepatic cholangiocarcinoma — the hilar first concept
title_full_unstemmed A surgical strategy for intrahepatic cholangiocarcinoma — the hilar first concept
title_short A surgical strategy for intrahepatic cholangiocarcinoma — the hilar first concept
title_sort surgical strategy for intrahepatic cholangiocarcinoma — the hilar first concept
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404569/
https://www.ncbi.nlm.nih.gov/pubmed/37544932
http://dx.doi.org/10.1007/s00423-023-03023-y
work_keys_str_mv AT nevermannnora asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT bodejulia asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT vischermaxine asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT feldbruggelina asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT knittersebastian asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT krenzienfelix asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT pelzeruwe asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT fehrenbachuli asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT auertimoalexander asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT lurjegeorg asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT schmelzlemoritz asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT pratschkejohann asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT schoningwenzel asurgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT nevermannnora surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT bodejulia surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT vischermaxine surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT feldbruggelina surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT knittersebastian surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT krenzienfelix surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT pelzeruwe surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT fehrenbachuli surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT auertimoalexander surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT lurjegeorg surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT schmelzlemoritz surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT pratschkejohann surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept
AT schoningwenzel surgicalstrategyforintrahepaticcholangiocarcinomathehilarfirstconcept